AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17707010 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 54
Study 16375657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GbE) at daily doses of 120 mg
Number of subjects: 513
Study 16375657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GbE) at daily doses of 240 mg
Number of subjects: 513
Study 16375657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 12195242 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitalon (Ala‐Glu‐Asp‐Gly)
Number of subjects: 0
Study 9626341 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR
Number of subjects: 39
Study 9626341 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 8566919 — intervention group
Group type: EXPERIMENTAL
Intervention: Head space-solid phase microextraction and gas chromatography-mass spectrometry/chemical ionization selected ion monitoring
Number of subjects: 0
Study 2669441 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 60
Study 2669441 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clomipramine
Number of subjects: 60
Study 2669441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1102484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐A ointment
Number of subjects: 52
Study 1102484 — intervention group
Group type: COMPARATOR
Intervention: IDU ointment
Number of subjects: 52
Study 31880826 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3023414
Number of subjects: 28
Study 31174526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily with aspirin 81 mg
Number of subjects: 70
Study 31174526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily without aspirin
Number of subjects: 70
Study 31174526 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg
Number of subjects: 70
Study 28946020 — intervention group
Group type: EXPERIMENTAL
Intervention: Power posing
Number of subjects: 73
Study 28946020 — intervention group
Group type: COMPARATOR
Intervention: Submissive posing
Number of subjects: 73
Study 28946020 — intervention group
Group type: COMPARATOR
Intervention: Rest (no posing)
Number of subjects: 73
Study 25727679 — intervention group
Group type: EXPERIMENTAL
Intervention: Child treated
Number of subjects: 55
Study 25727679 — intervention group
Group type: EXPERIMENTAL
Intervention: Child treated and parent participates in the course
Number of subjects: 55
Study 25727679 — intervention group
Group type: COMPARATOR
Intervention: Wait-list for 12 weeks
Number of subjects: 55
Study 25727679 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid disorders
Number of subjects: 55
Study 23713812 — intervention group
Group type: COMPARATOR
Intervention: IL‐1RN2/2 genotype
Number of subjects: 140
Study 23713812 — intervention group
Group type: COMPARATOR
Intervention: IL‐1RN1/2 genotype
Number of subjects: 140
Study 23713812 — intervention group
Group type: COMPARATOR
Intervention: Allele 2 of IL‐1RN gene
Number of subjects: 140
Study 23713812 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels
Number of subjects: 140
Study 21550027 — intervention group
Group type: EXPERIMENTAL
Intervention: Amolimogene (microparticle encapsulated pDNA vaccine)
Number of subjects: 21
Study 19301724 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) with 0.125% levobupivacaine and morphine 0.0125 mg/ml (4 ml/hr)
Number of subjects: 61
Study 19301724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with 0.125% levobupivacaine (8 ml/hr)
Number of subjects: 61
Study 17201996 — intervention group
Group type: EXPERIMENTAL
Intervention: R,S‐citalopram (20 mg)
Number of subjects: 8
Study 17201996 — intervention group
Group type: COMPARATOR
Intervention: S‐citalopram (10 mg)
Number of subjects: 8
Study 17201996 — intervention group
Group type: EXPERIMENTAL
Intervention: R,S‐citalopram
Number of subjects: 8
Study 17201996 — intervention group
Group type: COMPARATOR
Intervention: S‐citalopram
Number of subjects: 8
Study 15467526 — intervention group
Group type: COMPARATOR
Intervention: beta2 sympathomimetics
Number of subjects: 238
Study 15467526 — intervention group
Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate (GTN)
Number of subjects: 238
Study 15467526 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 238
Study 15170981 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given monthly (arm A)
Number of subjects: 54
Study 15170981 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given every 2 months (arm B)
Number of subjects: 54
Study 11408900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (25 mg) injected once per week for 5 weeks
Number of subjects: 78
Study 11408900 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (2 mg) injected once per week for 5 weeks
Number of subjects: 78
Study 11408900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SH and steroid)
Number of subjects: 78
Study 9412547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg)
Number of subjects: 12
Study 9412547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8500235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate (H-I)
Number of subjects: 1446
Study 8500235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 1446
Study 8500235 — intervention group
Group type: COMPARATOR
Intervention: Placebo and prazosin
Number of subjects: 1446
Study 8500235 — intervention group
Group type: EXPERIMENTAL
Intervention: H-I and Enalapril
Number of subjects: 1446
Study 8500235 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LVEF (> 5) from baseline
Number of subjects: 1446
Study 2892862 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 16
Study 2892862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin administration
Number of subjects: 16
Study 2892862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29107439 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 110
Study 29107439 — intervention group
Group type: COMPARATOR
Intervention: Low Extremities Exercise (LEE)
Number of subjects: 110
Study 26733057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovaleap® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Number of subjects: 299
Study 26733057 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Number of subjects: 299
Study 26733057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovaleap® and Gonal-f®
Number of subjects: 299
Study 25069431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or tianepine with cognitive-behavioral therapy, supportive therapy, or psychodynamic therapy
Number of subjects: 821
Study 25069431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 821
Study 24094792 — intervention group
Group type: EXPERIMENTAL
Intervention: INCREASE PA
Number of subjects: 52
Study 24094792 — intervention group
Group type: COMPARATOR
Intervention: DECREASE TV
Number of subjects: 52
Study 24094792 — intervention group
Group type: EXPERIMENTAL
Intervention: INCREASE PA+DECREASE TV
Number of subjects: 52
Study 21627399 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (500 mg per capsule, 3 capsules daily for 2 months)
Number of subjects: 40
Study 21627399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules identical in colour and size)
Number of subjects: 40
Study 18196350 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9978
Study 18196350 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 9978
Study 18196350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 9978
Study 18196350 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of 1-year mortality
Number of subjects: 9978
Study 18196350 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day follow-up
Number of subjects: 9978
Study 17019956 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser radiation on the adrenal projection region
Number of subjects: 0
Study 14582592 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium aluminate cement (CAC)
Number of subjects: 57
Study 14582592 — intervention group
Group type: COMPARATOR
Intervention: Resin composite (RC)
Number of subjects: 57
Study 10765039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefotiam dihydrochloride (CTM) 2 g on induction of anesthesia
Number of subjects: 207
Study 10765039 — intervention group
Group type: COMPARATOR
Intervention: Oral cefpodoxime proxetil (CPDX-PR) 100 mg twice daily from day 0 to day 2
Number of subjects: 207
Study 8685664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay ($3.40/hour)
Number of subjects: 150
Study 8685664 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in work activity
Number of subjects: 150
Study 1321542 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms.kg‐1 rocuronium
Number of subjects: 0
Study 1321542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 suxamethonium preceded by 10 mg gallamine
Number of subjects: 0
Study 1321542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no muscle relaxant)
Number of subjects: 0
Study 6376208 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg/triamterene 50 mg once-daily oral doses
Number of subjects: 0
Study 6376208 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg alone
Number of subjects: 0
Study 31686529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed orthosis
Number of subjects: 40
Study 31686529 — intervention group
Group type: COMPARATOR
Intervention: low-temperature thermoplastic plate orthosis
Number of subjects: 40
Study 31810850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC) therapy
Number of subjects: 50
Study 31810850 — intervention group
Group type: COMPARATOR
Intervention: Conventional bolster dressing (CBD)
Number of subjects: 50
Study 26559710 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase physical activity (iPA)
Number of subjects: 204
Study 26559710 — intervention group
Group type: COMPARATOR
Intervention: Decrease sedentary leisure (dSED)
Number of subjects: 204
Study 26559710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily changes in MVPA
Number of subjects: 204
Study 25027479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physical activity program performed in a work environment for 9 months
Number of subjects: 68
Study 25027479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study 23210527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week group cognitive-behavioural stress management (CBSM) programme plus standard care
Number of subjects: 355
Study 23210527 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 355
Study 20645992 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioural Assessment and Intervention Program (IBAIP)
Number of subjects: 176
Study 20645992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 176
Study 19884268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatments
Number of subjects: 196
Study 19884268 — intervention group
Group type: EXPERIMENTAL
Intervention: No funding
Number of subjects: 196
Study 19884268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter RCT
Number of subjects: 196
Study 17572579 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolence30 (30 mg/ml)
Number of subjects: 12
Study 17572579 — intervention group
Group type: COMPARATOR
Intervention: Zyplast (bovine cross-linked collagen)
Number of subjects: 12
Study 15194014 — intervention group
Group type: EXPERIMENTAL
Intervention: tenecteplase (TNK‐t‐PA)
Number of subjects: 266
Study 15194014 — intervention group
Group type: COMPARATOR
Intervention: alteplase
Number of subjects: 266
Study 12137881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy
Number of subjects: 0
Study 12137881 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin therapy (three cycles of urinary or recombinant gonadotropins)
Number of subjects: 0
Study 10981089 — intervention group
Group type: EXPERIMENTAL
Intervention: Various classes of blood pressure-lowering agents
Number of subjects: 270000
Study 10981089 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic overviews and meta-analyses of major ongoing trials
Number of subjects: 270000
Study 7789479 — intervention group
Group type: EXPERIMENTAL
Intervention: Device No. 1
Number of subjects: 13
Study 7789479 — intervention group
Group type: COMPARATOR
Intervention: Technician effects
Number of subjects: 13
Study 7789479 — intervention group
Group type: COMPARATOR
Intervention: Team effects
Number of subjects: 13
Study 7789479 — intervention group
Group type: COMPARATOR
Intervention: Device effects
Number of subjects: 13
Study 2206033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once a day with the morning meal (qam)
Number of subjects: 290
Study 2206033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once a day with the evening meal (qpm)
Number of subjects: 290
Study 2206033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg qpm
Number of subjects: 290
Study 2206033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 290
Study 2206033 — intervention group
Group type: COMPARATOR
Intervention: Probucol 500 mg twice daily
Number of subjects: 290
Study 388220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (alternate-day treatment for at least eight weeks)
Number of subjects: 72
Study 388220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 6354552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with lidocaine
Number of subjects: 31
Study 6354552 — intervention group
Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with saline
Number of subjects: 31
Study 6354552 — intervention group
Group type: COMPARATOR
Intervention: Circumcision without DPNB
Number of subjects: 31
Study 30055852 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HAM-D17)
Number of subjects: 237
Study 30055852 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-item Hamilton Depression Rating Scale (HAM-D6)
Number of subjects: 237
Study 29411238 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospital care (nurse and physician home visits, intravenous medications, continuous monitoring, video communication, point‐of‐care testing)
Number of subjects: 20
Study 29411238 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospital care
Number of subjects: 20
Study 29411238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 27475700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel containing chitosan, 0.2% chlorhexidine, allantoin and dexpanthenol applied 10 ml three times a day for 10 days
Number of subjects: 50
Study 27475700 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gel applied)
Number of subjects: 50
Study 24608624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir for 1 week
Number of subjects: 59
Study 24608624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 22499565 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated start
Number of subjects: 9
Study 22499565 — intervention group
Group type: COMPARATOR
Intervention: Bunched start
Number of subjects: 9
Study 22499565 — intervention group
Group type: COMPARATOR
Intervention: Medium start
Number of subjects: 9
Study 20028967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 10 weeks
Number of subjects: 24
Study 20028967 — intervention group
Group type: COMPARATOR
Intervention: Obese controls (n = 12)
Number of subjects: 24
Study 20028967 — intervention group
Group type: COMPARATOR
Intervention: Endurance-trained athletes (n = 15)
Number of subjects: 24
Study 18806028 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control system for propofol administration
Number of subjects: 40
Study 18806028 — intervention group
Group type: COMPARATOR
Intervention: Manual control group (anesthesiologist titrated propofol)
Number of subjects: 40
Study 15577823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1 mg/kg)
Number of subjects: 12
Study 15577823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11379646 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of local anesthetic (Group I)
Number of subjects: 60
Study 11379646 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic (Group II)
Number of subjects: 60
Study 11379646 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioid (Group III)
Number of subjects: 60
Study 9249783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (2 x 5 mg daily for normotensive patients; 2 x 10 mg to 2 x 20 mg daily for hypertensive patients)
Number of subjects: 0
Study 9249783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8491391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14
Number of subjects: 32
Study 8491391 — intervention group
Group type: COMPARATOR
Intervention: Sucralphate 4 g/day
Number of subjects: 32
Study 2891631 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fulguration of endometriotic implants (Group A)
Number of subjects: 123
Study 2891631 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - implants left intact
Number of subjects: 123
Study 27677562 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate levels equal to or above the median (5.1 mg/dl)
Number of subjects: 942
Study 27677562 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest urate quartile
Number of subjects: 942
Study 27677562 — intervention group
Group type: COMPARATOR
Intervention: Lowest urate quartile
Number of subjects: 942
Study 27110098 — intervention group
Group type: COMPARATOR
Intervention: FDC_EVO5/MET1000
Number of subjects: 36
Study 27110098 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC_EVO5/MET1000 under fed condition
Number of subjects: 36
Study 24534779 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotically assisted body weight supported treadmill training (RABWSTT)
Number of subjects: 21
Study 24534779 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cycle ergometry
Number of subjects: 21
Study 24534779 — intervention group
Group type: COMPARATOR
Intervention: RABWSTT and arm ergometry
Number of subjects: 21
Study 22300367 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (2 g)
Number of subjects: 8
Study 22300367 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (100 µg or 2 g) alone
Number of subjects: 8
Study 19563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Branemark implant system (two-stage screw type)
Number of subjects: 30
Study 17993763 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg qd
Number of subjects: 30
Study 17993763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15889369 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 8
Study 11605101 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg alcohol
Number of subjects: 32
Study 11605101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11605101 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (4.35+/‐0.53 g/kg per week)
Number of subjects: 32
Study 11605101 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drink
Number of subjects: 32
Study 9481347 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirlpool therapy
Number of subjects: 63
Study 8038616 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex
Number of subjects: 34
Study 8038616 — intervention group
Group type: COMPARATOR
Intervention: 5% human serum albumin (0.01 ml/kg)
Number of subjects: 34
Study 3149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 105
Study 3149929 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus Gentamicin
Number of subjects: 105
Study 31138332 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin plus gemcitabine (EG)
Number of subjects: 118
Study 31138332 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG)
Number of subjects: 118
Study 28972673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 129
Study 28972673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 28972673 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 129
Study 26093641 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2338
Study 26093641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2338
Study 25208361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU)
Number of subjects: 61
Study 25208361 — intervention group
Group type: EXPERIMENTAL
Intervention: dentin burnishing with fiber‐resin burs (STB)
Number of subjects: 61
Study 25208361 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Coat One (MSC)
Number of subjects: 61
Study 20796082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran feed (RBF)
Number of subjects: 18
Study 20796082 — intervention group
Group type: COMPARATOR
Intervention: Placebo feed (PF)
Number of subjects: 18
Study 20796082 — intervention group
Group type: COMPARATOR
Intervention: Control (CRT)
Number of subjects: 18
Study 20796082 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD)
Number of subjects: 18
Study 20796082 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD)
Number of subjects: 18